The DOI matches its Crossref record; 313 of the 313 references it cites were found in a registry or an index.
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
Open accessAbstract
This PharmGKB summary briefly discusses the CYP2C19 gene and current understanding of its function, regulation, and pharmacogenomic relevance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., et al. (1993) · DNA and Cell Biology · doi:10.1089/dna.1993.12.1 · Cited by 1,655
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Self-citationMetabolism and Disposition Kinetics of Nicotine
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.3 · Cited by 1,321
Nicotine Chemistry, Metabolism, Kinetics and Biomarkers
Benowitz, N. L., Hukkanen, J., & Jacob, P. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-69248-5_2 · Cited by 1,179
Mega, J. L., Simon, T., Collet, J.-P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., et al. (2010) · JAMA · doi:10.1001/jama.2010.1543 · Cited by 1,135
Self-citationPharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.064 · Cited by 1,015
Ho, P. M. (2009) · JAMA · doi:10.1001/jama.2009.261 · Cited by 1,007
Collet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
Self-citationThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
Self-citationAromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Ding, X., & Kaminsky, L. S. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140251 · Cited by 822
Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., & Fukushima, M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00010 · Cited by 820
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400293200 · Cited by 705
Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior
The ENGAGE Consortium, Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.573 · Cited by 689
Li, X.-Q., Andersson, T. B., Ahlström, M., & Weidolf, L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.821 · Cited by 644
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A. (2010) · Circulation · doi:10.1161/circulationaha.109.885194 · Cited by 585
Biochemistry and molecular biology of the human CYP2C subfamily
Goldstein, J. A., & de Morais, S. M. F. (1994) · Pharmacogenetics · doi:10.1097/00008571-199412000-00001 · Cited by 529
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Female sex and oral contraceptive use accelerate nicotine metabolism
BENOWITZ, N., LESSOVSCHLAGGAR, C., SWAN, G., & JACOBIII, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.008 · Cited by 486
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 484
Self-citationWriting Committee Members, Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., et al. (2010) · Circulation · doi:10.1161/cir.0b013e318202f701 · Cited by 451
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1
DEMPSEY, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.011 · Cited by 429
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08453-3 · Cited by 418
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
Rahman, A., Korzekwa, K., Grogan, J., et al. (1994) · PubMed · Cited by 388
Hulot, J.-S., Collet, J.-P., Silvain, J., Pena, A., Bellemain-Appaix, A., Barthélémy, O., Cayla, G., Beygui, F., & Montalescot, G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.071 · Cited by 383
Self-citationThe CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
Yamano, S., Tatsuno, J., & Gonzalez, F. J. (1990) · Biochemistry · doi:10.1021/bi00457a031 · Cited by 383
Structure of Human Microsomal Cytochrome P450 2C8
Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312516200 · Cited by 382
Spina, E., Santoro, V., & D'Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 361
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321
Induction of CYP2C genes in human hepatocytes in primary culture.
Gerbal‐Chaloin, S., Pascussi, J., Pichard‐Garcia, L., Daujat‐Chavanieu, M., Waechter, F., Fabre, J.-M., Carrère, N., & Maurel, P. (2001) · PubMed · Cited by 318
Schoedel, K. A., Hoffmann, E. B., Rao, Y., Sellers, E. M., & Tyndale, R. F. (2004) · Pharmacogenetics · doi:10.1097/00008571-200409000-00006 · Cited by 315
Rae, J. M., Johnson, M. D., Lippman, M. E., & Flockhart, D. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29202-8 · Cited by 306
Li, X.-Q., Björkman, A., Andersson, T. B., Ridderström, M., & Masimirembwa, C. M. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.399 · Cited by 288
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima, M., Yamamoto, T., Nunoya, K., Yokoi, T., Nagashima, K., Inoue, K., Funae, Y., Shimada, N., Kamataki, T., & Kuroiwa, Y. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12887-5 · Cited by 284
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation
LERMAN, C., TYNDALE, R., PATTERSON, F., WILEYTO, E., SHIELDS, P., PINTO, A., & BENOWITZ, N. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.02.006 · Cited by 280
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*
Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.011 · Cited by 267
Csajka, C., Marzolini, C., Fattinger, K., Décosterd, L. A., Fellay, J., Telenti, A., Biollaz, J., & Buclin, T. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.22 · Cited by 266
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Li‐Wan‐Po, A., Girard, T., Farndon, P., Cooley, C., & Lithgow, J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03578.x · Cited by 262
Furuta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Rifkind, A. B., Lee, C., Chang, T. K. H., & Waxman, D. J. (1995) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(95)90023-3 · Cited by 251
Kesterson, J. W., Granneman, R. G., & Machinist, J. M. (1984) · Hepatology · doi:10.1002/hep.1840040609 · Cited by 250
Cytochrome P-450—Catalyzed Formation of Δ4-VPA, a Toxic Metabolite of Valproic Acid
Rettie, A. E., Rettenmeier, A. W., Howald, W. N., & Baillie, T. A. (1987) · Science · doi:10.1126/science.3101178 · Cited by 250
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways
Bort, R., Macé, K., Boobis, A., Gómez-Lechón, M.-J., Pfeifer, A., & Castell, J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00167-7 · Cited by 240
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.010 · Cited by 239
Sarasquete, M. E., García-Sanz, R., Marín, L., Alcoceba, M., Chillón, M. C., Balanzategui, A., Santamaria, C., Rosiñol, L., de la Rubia, J., Hernandez, M. T., et al. (2008) · Blood · doi:10.1182/blood-2008-04-147884 · Cited by 238
Marsh, S., Paul, J., King, C. R., Gifford, G., McLeod, H. L., & Brown, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4752 · Cited by 238
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01354-0 · Cited by 235
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
Yamazaki, H., Inoue, K., Hashimoto, M., & Shimada, T. (1999) · Archives of Toxicology · doi:10.1007/s002040050588 · Cited by 235
Li, X.-Q., Bj�rkman, A., Andersson, T. B., Gustafsson, L. L., & Masimirembwa, C. M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0636-9 · Cited by 232
Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 232
Rao, Y., Hoffmann, E., Zia, M., Bodin, L., Zeman, M., Sellers, E. M., & Tyndale, R. F. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23106-0 · Cited by 231
Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450
Johansson, I., & Ingelman-Sundberg, M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq374 · Cited by 231
Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
Hamman, M. A., Thompson, G. A., & Hall, S. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00143-3 · Cited by 230
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Valente, S., Antoniucci, D., Abbate, R., & Gensini, G. F. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1b2be · Cited by 230
Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance
TOTAH, R., & RETTIE, A. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.267 · Cited by 225
NAKAJIMA, M., FUKAMI, T., YAMANAKA, H., HIGASHI, E., SAKAI, H., YOSHIDA, R., KWON, J., MCLEOD, H., & YOKOI, T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.012 · Cited by 222
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism in Vitro
Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D. A., & Zanger, U. M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.547 · Cited by 222
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
BENOWITZ, N., SWAN, G., JACOBIII, P., LESSOVSCHLAGGAR, C., & TYNDALE, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.011 · Cited by 217
Nicotine Blood Levels and Subjective Craving for Cigarettes
Jarvik, M. E., Madsen, D. C., Olmstead, R. E., Iwamoto-Schaap, P. N., Elins, J. L., & Benowitz, N. L. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00261-6 · Cited by 217
Geisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., Zuern, C., Moerike, K., Gawaz, M., & Schwab, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.9.1251 · Cited by 213
Bidstrup, T. B., Bjørnsdottir, I., Sidelmann, U. G., Thomsen, M. S., & Hansen, K. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01862.x · Cited by 209
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko, J. W., Sukhova, N., Thacker, D. L., Chen, P., & Flockhart, D. A. (1997) · PubMed · Cited by 209
Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L., & Goldstein, J. A. (1991) · Biochemistry · doi:10.1021/bi00227a012 · Cited by 209
Fujieda, M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh258 · Cited by 208
Svensson, & Ashton (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00044.x · Cited by 205
Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013169 · Cited by 200
Ferguson, R. J., De Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37213-1 · Cited by 199
Marill, J., Cresteil, T., Lanotte, M., & Chabot, G. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12706-x · Cited by 197
Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes
Draper, A. J., Madan, A., & Parkinson, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9964 · Cited by 191
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity
Miles, J. S., McLaren, A. W., Forrester, L. M., Glancey, M. J., Lang, M. A., & Wolf, C. R. (1990) · Biochemical Journal · doi:10.1042/bj2670365 · Cited by 190
Gene structure ofCYP2C8 and extrahepatic distribution of the human CYP2Cs
Klose, T. S., Blaisdell, J. A., & Goldstein, J. A. (1999) · Journal of Biochemical and Molecular Toxicology · Cited by 189
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Kobayashi, K., Urashima, K., Shimada, N., & Chiba, K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00843-7 · Cited by 188
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186
Variability in human cytochrome P450 paclitaxel metabolism.
Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A., & Relling, M. V. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12102-2 · Cited by 186
Projean, D., Baune, B., Farinotti, R., Flinois, J.-P., Beaune, P., Taburet, A.-M., & Ducharme, J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.748 · Cited by 185
Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8
Walsky, R. L., Gaman, E. A., & Obach, R. S. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004270642 · Cited by 184
Malaiyandi, V, Lerman, C., Benowitz, N. L., Jepson, C., Patterson, F., & Tyndale, R. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001794 · Cited by 183
GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Oscarson, M., McLellan, R. A., Gullstén, H., Agúndez, J. A. G., Benı́tez, J., Rautio, A., Raunio, H., Pelkonen, O., & Ingelman-Sundberg, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01364-2 · Cited by 181
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01833.x · Cited by 180
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
Tracy, T. S., Korzekwa, K. R., Gonzalez, F. J., & Wainer, I. W. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00923.x · Cited by 180
Zabalza, M., Subirana, I., Sala, J., Lluis-Ganella, C., Lucas, G., Tomás, M., Masiá, R., Marrugat, J., Brugada, R., & Elosua, R. (2012) · Heart · doi:10.1136/hrt.2011.227652 · Cited by 180
Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8
Leo, M. A., Lasker, J. M., Raucy, J. L., Kim, C.-I., Black, M., & Lieber, C. S. (1989) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(89)90112-4 · Cited by 178
Zeldin, D. C., Dubois, R. N., Falck, J. R., & Capdevila, J. H. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1438 · Cited by 177
McDonagh, E. M., Whirl-Carrillo, M., Garten, Y., Altman, R. B., & Klein, T. E. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.94 · Cited by 174
Self-citationWassenaar, C. A., Dong, Q., Wei, Q., Amos, C. I., Spitz, M. R., & Tyndale, R. F. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr237 · Cited by 174
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
Wen, X., Wang, J.-S., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.631 · Cited by 173
Sofi, F., Giusti, B., Marcucci, R., Gori, A. M., Abbate, R., & Gensini, G. F. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.21 · Cited by 172
Parikh, S., Ouedraogo, J.-B., Goldstein, J. A., Rosenthal, P. J., & Kroetz, D. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100122 · Cited by 172
Ho, M., Mwenifumbo, J., Al Koudsi, N., Okuyemi, K., Ahluwalia, J., Benowitz, N., & Tyndale, R. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.19 · Cited by 171
Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15077-5 · Cited by 166
Tiroch, K. A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schömig, A., & Kastrati, A. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.039 · Cited by 166
Nakajima, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.112688 · Cited by 165
Grasm�der, K., Verwohlt, P., Rietschel, M., Dragicevic, A., M�ller, M., Hiemke, C., Freymann, N., Zobel, A., Maier, W., & Rao, M. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0766-8 · Cited by 161
Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F. P., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14927-6 · Cited by 161
Kiang, T. K. L., Ho, P. C., Anari, M. R., Tong, V., Abbott, F. S., & Chang, T. K. H. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl096 · Cited by 160
Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample
Peters, E. J., Slager, S. L., Kraft, J. B., Jenkins, G. D., Reinalda, M. S., McGrath, P. J., & Hamilton, S. P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001872 · Cited by 159
Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor
Higashi, E., Fukami, T., Itoh, M., Kyo, S., Inoue, M., Yokoi, T., & Nakajima, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016568 · Cited by 159
Wen, X., Wang, J., Kivistö, K. T., Neuvonen, P. J., & Backman, J. T. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01474.x · Cited by 158
Pitarque, M., von Richter, O., Oke, B., Berkkan, H., Oscarson, M., & Ingelman‐Sundberg, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4990 · Cited by 157
Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka‐Akita, H., Sawamura, Y.-I., Yokota, J., Nemoto, N., Sato, K., & Kamataki, T. (2002) · PubMed · Cited by 155
Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-Ene-Valproic Acid
Sadeque, A. J. M., Fisher, M. B., Korzekwa, K. R., Gonzalez, F. J., & Rettie, A. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37076-4 · Cited by 155
CYP2C19 variation and citalopram response
Mrazek, D. A., Biernacka, J. M., O’Kane, D. J., Black, J. L., Cunningham, J. M., Drews, M. S., Snyder, K. A., Stevens, S. R., Rush, A. J., & Weinshilboum, R. M. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328340bc5a · Cited by 154
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
di Iulio, J., Fayet, A., Arab‐Alameddine, M., Rotger, M., Lubomirov, R., Cavassini, M. L., Furrer, H., Günthard, H. F., Colombo, S. F., Csajka, C., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328328d577 · Cited by 153
The Role ofCYP2A6in the Emergence of Nicotine Dependence in Adolescents
Audrain-McGovern, J. E., Koudsi, N. A., Rodriguez, D., Wileyto, E. P., Shields, P. G., & Tyndale, R. F. (2006) · PEDIATRICS · doi:10.1542/peds.2006-1583 · Cited by 149
Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 149
Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical Studies
Daily, E. B., & Aquilante, C. L. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.82 · Cited by 148
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy, J. L., KEMPER, B. W., Bornheim, L. M., Hassett, C., Omiecinski, C. J., & Johnson, E. F. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.0013 · Cited by 146
Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes
Raucy, J. L., Mueller, L., Duan, K., Allen, S. W., Strom, S. C., & Lasker, J. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033837 · Cited by 146
Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman‐Sundberg, M., Eliasson, E., & Bertilsson, L. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03104.x · Cited by 146
Jaakkola, T., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_437.x · Cited by 145
Wortham, M., Czerwiński, M., He, L., Parkinson, A., & Wan, Y. Y. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016436 · Cited by 145
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Yaşar, Ü., Lundgren, S., Eliasson, E., Bennet, A. M., Wiman, B., Fairé, U. D., & Rane, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02592-5 · Cited by 143
Lc, M., & Daly, A. K. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00356-7 · Cited by 143
PharmGKB summary: fluoropyrimidine pathways
Thorn, C. F., Marsh, S., Whirl‐Carrillo, M., McLeod, H. L., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833c6107 · Cited by 142
Self-citationKamiyama, Y., Matsubara, T., Yoshinari, K., Nagata, K., Kamimura, H., & Yamazoe, Y. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.287 · Cited by 142
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport
Kerb, R., Fux, R., Mörike, K., Kremsner, P. G., Gil, J. P., Gleiter, C. H., & Schwab, M. G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70320-2 · Cited by 142
A single-nucleotide polymorphism tagging set for human drug metabolism and transport
Ahmadi, K. R., Weale, M. E., Xue, Z., Soranzo, N., Yarnall, D. P., Briley, J. D., Maruyama, Y., Kobayashi, M., Wood, N. W., Spurr, N. K., et al. (2004) · Nature Genetics · doi:10.1038/ng1488 · Cited by 142
Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes
Kim, K., Park, J. Y., Lee, J., et al. (2003) · Archives of Pharmacal Research · doi:10.1007/bf02976712 · Cited by 140
INVOLVEMENT OF CYP3A4, CYP2C8, AND CYP2D6 IN THE METABOLISM OF (R)- AND (S)-METHADONE IN VITRO
Wang, J.-S., & DeVane, C. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.742 · Cited by 140
Efavirenz in the therapy of HIV infection
Rakhmanina, N. Y., & van den Anker, J. N. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903483207 · Cited by 139
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19
Hoffman, S. M. G., Nelson, D. R., & Keeney, D. S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200111000-00007 · Cited by 138
An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 Alleles
Xu, C. D., Rao, Y. S., Xu, B. Q., Hoffmann, E. B., Jones, J. P., Sellers, E. M., & Tyndale, R. F. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6209 · Cited by 137
Yoshida, R. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00090-0 · Cited by 134
Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior
Tyndale, R. F., & Sellers, E. M. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200202000-00026 · Cited by 133
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
Leskelä, S., Jara, C., Leandro-Garcia, L. J., Martínez, A., García-Donás, J., Hernando, S., Hurtado, A., Vicario, J. C. C., Montero‐Conde, C., Landa, I., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.13 · Cited by 132
Identification and functional characterization of new potentially defective alleles of human CYP2C19
Blaisdell, J. A., Mohrenweiser, H. W., Jackson, J., Ferguson, S., Coulter, S. J., Chanas, B., Xi, T., Ghanayem, B. I., & Goldstein, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200212000-00004 · Cited by 132
Pearce, R. E., Vakkalagadda, G. R., & Leeder, J. S. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1170 · Cited by 132
Klotz, U. E. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44297 · Cited by 132
Arab‐Alameddine, M., di Iulio, J., Buclin, T., Rotger, M., Lubomirov, R., Cavassini, M. L., Fayet, A., Decosterd, L. A., Eap, C. B., Biollaz, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.271 · Cited by 129
Matsumoto, K., Ikawa, K., Abematsu, K., Fukunaga, N., Nishida, K., Fukamizu, T., Shimodozono, Y., Morikawa, N., Takeda, Y., & Yamada, K. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.008 · Cited by 129
Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I., & Blaisdell, J. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37748-1 · Cited by 127
Phase I Metabolic Genes and Risk of Lung Cancer: Multiple Polymorphisms and mRNA Expression
Rotunno, M., Yu, K. F., Lubin, J. H., Consonni, D., Pesatori, A. C., Goldstein, A. M., Goldin, L. R., Wacholder, S., Welch, R., Burdette, L. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005652 · Cited by 126
Rodríguez‐Antona, C., Gomez, A. V., Karlgren, M., Sim, S. C., & Ingelman‐Sundberg, M. (2009) · Human Genetics · doi:10.1007/s00439-009-0748-0 · Cited by 126
Kirchheiner, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00121-8 · Cited by 126
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
Kirchheiner, J., THOMAS, S., Bauer, S., Tomalik‐Scharte, D., Hering, U., Doroshyenko, O., Jetter, A., Stehle, S., Tsahuridu, M., & Meineke, I. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.008 · Cited by 126
The Transcriptional Regulation of the Human CYP2C Genes
Chen, Y., & Goldstein, J. A. (2009) · Current Drug Metabolism · doi:10.2174/138920009789375397 · Cited by 126
Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases
Johnson, E. F., & Stout, C. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.190 · Cited by 126
Daigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., Tanabe, S., Saigenji, K., Nagayama, S., Ikeda, K., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00005 · Cited by 125
Thorn, C. F., Aklillu, E., McDonagh, E. M., Klein, T. E., & Altman, R. B. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283505d5e · Cited by 124
Self-citationO’Loughlin, J. L., Paradis, G., Kim, W., DiFranza, J. R., Meshefedjian, G. A., McMillan-Davey, E., Wong, S., Hanley, J., & Tyndale, R. F. (2004) · Tobacco Control · doi:10.1136/tc.2003.007070 · Cited by 123
A 2.4-Megabase Physical Map Spanning the CYP2C Gene Cluster on Chromosome 10q24
Gray, I. C., Nobile, C., Muresu, R., Ford, S., & Spurr, N. K. (1995) · Genomics · doi:10.1006/geno.1995.1149 · Cited by 120
Genome-wide association study of smoking behaviours in patients with COPD
Siedliński, M., Cho, M. H., Bakke, P. S., Gulsvik, A., Lomas, D. A., Anderson, W. J., Kong, X., Rennard, S. I., Beaty, T. H., Hokanson, J. E., et al. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200154 · Cited by 119
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119
Kwara, A., Lartey, M. Y., Sagoe, K. W. C., Rzek, N. L., & Court, M. H. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03368.x · Cited by 117
Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6
Di, Y. M., Chow, V., Yang, L., & Zhou, S.-F. (2009) · Current Drug Metabolism · doi:10.2174/138920009789895507 · Cited by 117
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
Hertz, D. L., Roy, S., Motsinger‐Reif, A. A., Drobish, A. A., Clark, L. S., McLeod, H. L., Carey, L., & Dees, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt018 · Cited by 116
The xenobiotic inhibitor profile of cytochrome P4502C8
Ong, C., Coulter, S., Birkett, D. J., Bhasker, C. R., & Miners, J. O. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00316.x · Cited by 115
Rifampin decreases the plasma concentrations and effects of repaglinide
Niemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111183 · Cited by 115
Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level
Strasser, A. A., Benowitz, N. L., Pinto, A., Tang, K. Z., Hecht, S. S., Carmella, S. G., Tyndale, R. F., & Lerman, C. E. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0674 · Cited by 115
Bloom, A. J., Hinrichs, A. L., Wang, J. C. C., von Weymarn, L. B., Kharasch, E. D., Bierut, L. J., Goate, A., & Murphy, S. E. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328346e8c0 · Cited by 114
Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes
Nadin, L., & Murray, M. T. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00192-6 · Cited by 114
Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone
Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018010 · Cited by 114
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
Simonsson, U. S. H. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00092-4 · Cited by 113
Desta, Z., Kreutz, Y., Nguyen, A., Li, L., Skaar, T. C., Kamdem, L. K., Henry, N. L., Hayes, D. F., Storniolo, A. M., Stearns, V., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.174 · Cited by 111
Katz, J., Gong, Y., Salmasinia, D., Hou, W., Burkley, B., Ferreira, P., Casanova, O. B., Langaee, T. Y., & Moreb, J. S. (2011) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2011.02.002 · Cited by 111
Loriot, M., Rebuissou, S., Oscarson, M., Cénée, S., Miyamoto, M., Ariyoshi, N., Kamataki, T., Hémon, D., Beaune, P. H., & Stücker, I. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00005 · Cited by 111
Lerman, C. E., Jepson, C., Wileyto, E. P., Patterson, F., Schnoll, R. A., Mroziewicz, M., Benowitz, N. L., & Tyndale, R. F. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.3 · Cited by 110
Ibeanu, G. C., Blaisdell, J. A., Ferguson, R. J., Ghanayem, B. I., Brøsen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., & Goldstein, J. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34944-4 · Cited by 110
3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression
Wang, J., Pitarque, M., & Ingelman‐Sundberg, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.035 · Cited by 108
Yasumori, T., Nagata, K., Yang, S. K., Chen, L., Murayama, N., Yamazoe, Y., & Kato, R. (1993) · Pharmacogenetics · doi:10.1097/00008571-199312000-00003 · Cited by 108
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients
Kurzawski, M., Gawronska-Szklarz, B., Wrześniewska, J., Siuda, A., Starzyñska, T., & Droździk, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0183-2 · Cited by 106
Agúndez, J. A. G., García‐Martín, E., & Martínez, C. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902970998 · Cited by 106
Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity Relationship
Cresteil, T., Monsarrat, B., Dubois, J., Sonnier, M., Alvinerie, P., & Guéritte, F. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.4.438 · Cited by 105
Busse, D., Cosme, J., Beaune, P. H., Kroemer, H., Eichelbaum, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. F. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168924 · Cited by 105
Komatsu, T., Yamazaki, H., Shimada, N., Nakajima, M., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13674-4 · Cited by 105
Padol, S., Yuan, Y., Thabane, M. E., Padol, I. T., & Hunt, R. H. (2007) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45188 · Cited by 105
Niemi, M., Backman, J. T., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.001 · Cited by 103
Cited by
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
Self-citationBiochemical verification of tobacco use and abstinence: 2019 update
Benowitz, N. L., Bernert, J. T., Foulds, J., Hecht, S. S., Jacob, P., Jarvis, M. J., Joseph, A., Oncken, C., & Piper, M. E. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz132 · Cited by 619
Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, Sr., Henning, S., Scott, S., Agúndez, J., Wingard, Jr., McLeod, H., Klein, T., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.583 · Cited by 404
Self-citationApplications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
El Rouby, N., Lima, J. J., & Johnson, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461835 · Cited by 263
Metadata
- Authors
- Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2012-02
- Volume
- 22
- Issue
- 2
- Pages
- 159-165
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025995483
- Cited by
- 261
- References
- 313
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.